Pfizer’s $4.9bn bet on obesity startup Metsera is looking promising, with 14.1% weight loss reported in a Phase IIb trial. In the VESPER-1 trial (NCT06712836), MET-097i, a glucagon-like peptide-1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results